Clearside Biomed Stock Price, News & Analysis

Clearside Biomedical (NASDAQ: CLSD) announced multiple upcoming presentations at medical conferences focusing on its suprachoroidal delivery technology and CLS-AX program for wet AMD treatment. The presentations will feature sub-group analyses from the Phase 2b ODYSSEY trial at the Angiogenesis and Macula Society conferences.

The company's Chief Medical Officer, Dr. Victor Chong, highlighted that suprachoroidal CLS-AX aims to deliver comparable 6-month therapeutic effects in most wet AMD patients, similar to other intravitreal TKIs in development, while offering more flexible dosing options. The technology potentially enables precise therapy application to the retina, which may improve safety compared to intravitreal treatments.

Recent presentations at Hawaiian Eye & Retina 2025 and the 3rd Annual Ophthalmic Drug Delivery Summit covered various aspects of suprachoroidal delivery. Upcoming presentations are scheduled at Angiogenesis 2025, The Macula Society Meeting, and the Wet AMD & Diabetic Eye Disease Drug Summit.

Clearside Biomedical (Nasdaq: CLSD) announced that its partner Arctic Vision has received regulatory approvals in Australia and Singapore for ARCATUS® (branded as XIPERE® in the U.S.) to treat uveitic macular edema (UME). This marks the first globally approved suprachoroidal therapy, utilizing Clearside's SCS Microinjector® platform for delivering treatments to the back of the eye.

Arctic Vision holds exclusive licensing rights for commercialization and development in Greater China, South Korea, Australia, New Zealand, India, and ASEAN Countries. The company reported positive Phase 3 UME clinical trial results in China in July 2024 and established a commercial partnership with Santen Pharmaceutical in November 2024 for commercialization rights in mainland China. Arctic Vision is also exploring ARVN001's potential for other retinal diseases, including diabetic macular edema.

Clearside Biomedical (NASDAQ: CLSD) announced the publication of critical insights into retinal drug development in the scientific journal Eye, based on a presentation by their Chief Medical Officer, Dr. Victor Chong, at the Edridge Green Lecture. The article, published in December 2024, provides a comprehensive overview of clinical trial design and regulatory pathways for drug development, particularly focusing on retinal diseases.

The publication covers key topics including clinical trial structure, efficacy and safety endpoints, and regulatory agency expectations. It highlights recent advancements like incorporating low-luminance vision as a secondary endpoint and examines case studies from age-related macular degeneration trials. The lecture also addressed geographic atrophy and diabetic retinopathy trials, emphasizing new anatomical endpoints and innovative drugs.

Clearside Biomedical (NASDAQ: CLSD) showcased its suprachoroidal delivery technology and pipeline programs at multiple medical meetings across Asia, Europe, and the United States. The company made a significant impact at the 17th Asia-Pacific Vitreo-Retina Society Congress in Singapore with presentations on ODYSSEY topline results, XIPERE® real-world data, and four posters on their suprachoroidal delivery platform. The company hosted three fully-attended demonstration sessions of their SCS Microinjector® technology. With over 10,000 injections performed to date, Clearside has established itself as a leader in suprachoroidal space delivery of therapeutic agents.

Clearside Biomedical (Nasdaq: CLSD) announced its Q3 2024 financial results and provided a corporate update. Key highlights include the successful completion of the ODYSSEY Phase 2b trial for CLS-AX in wet AMD, achieving all primary and secondary outcomes. The positive results support advancing CLS-AX to Phase 3 with a flexible dosing approach. Clearside also secured a commercial licensing agreement with Santen Pharmaceutical for rights in China, validating its suprachoroidal platform. Financially, Clearside reported a Q3 2024 net loss of $7.7 million, or $0.10 per share, compared to a $9.3 million net loss in Q3 2023. Revenue for Q3 2024 was $1.0 million, up from $0.9 million in Q3 2023. As of September 30, 2024, the company had $23.6 million in cash and equivalents, sufficient to fund operations into Q3 2025. The webcast and conference call are scheduled for today at 4:30 PM ET.

Clearside Biomedical (CLSD) announced that its Asia-Pacific partner, Arctic Vision, has signed a commercial collaboration agreement with Santen Pharmaceutical for ARVN001 (branded as XIPERE® in the US) for treating uveitic macular edema in China. Under the agreement, Arctic Vision grants Santen rights to commercialize ARVN001 in mainland China. The partnership validates Clearside's suprachoroidal delivery platform, which is now being utilized by major pharmaceutical companies including Santen, Bausch + Lomb, AbbVie, REGENXBIO, Aura Biosciences, and BioCryst. Arctic Vision recently reported positive Phase 3 trial results in China and has regulatory reviews ongoing in Australia and Singapore.

Clearside Biomedical (Nasdaq: CLSD), a company specializing in suprachoroidal space (SCS®) therapy delivery to the back of the eye, has announced its participation in the Stifel 2024 Healthcare Conference. George Lasezkay, President and CEO, and Victor Chong, Chief Medical Officer and EVP of R&D, will engage in a fireside chat on November 19, 2024, at 8:00 a.m. ET in New York.

The event will be accessible via webcast on Clearside's website under the Investors section, with the recording remaining available for three months following the presentation.

Clearside Biomedical (Nasdaq: CLSD) has appointed Tony Gibney as the new Chair of its Board of Directors, effective November 1, 2024. Gibney, who joined as an independent director in April 2024, succeeds Clay Thorp, who remains on the Board. Gibney brings over 30 years of biotechnology industry experience, most recently serving as Executive VP, Chief Business & Strategy Officer at Iveric Bio until its acquisition by Astellas Pharma in July 2023. The company highlights his strategic leadership in ophthalmics and capital markets expertise, particularly noting the recent ODYSSEY Phase 2b results with CLS-AX in wet AMD, which showed promising potential.

Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after market close. The company will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss results and provide a corporate update. Investors can access the webcast through Clearside's website under the Investors section, or join the call using domestic (877) 545-0523 or international (973) 528-0016 dial-in numbers with conference code 756568.